OptiBiotix Health’s (LON:OPTI) move to register five new microbial strains under the Budapest Treaty, could give it added clout at the negotiation table reckons Hybridan.
Strain registration protects ownership and allows OptiBiotix to build application patents around specific strains creating valuable assets.
“As OptiBiotix advances its programmes towards commercialisation it is vital that its know-how, microbial strains and processes are protected,” Hybridan said.
The strains generate novel oligosaccharides, put simply, carbohydrates that consist of a small number of sugars, and if successful, could replace 'unhealthy' sugars in many food products.
The oligosaccharide program is being progressed in conjunction with the Spanish National Research Council with human studies expected to start next year.
The cholesterol-busting supplement maker has also completed human studies on the cholesterol product which is now in pilot manufacturing studies.
“Strong intellectual product and scientific advances will strengthen OptiBiotix’s position at the bargaining table with well-resourced companies,” the broker said.
The share price has risen some 25% this quarter, and was 2.3% higher today to 49.4p.